ATE242253T1 - Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind - Google Patents

Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind

Info

Publication number
ATE242253T1
ATE242253T1 AT94925701T AT94925701T ATE242253T1 AT E242253 T1 ATE242253 T1 AT E242253T1 AT 94925701 T AT94925701 T AT 94925701T AT 94925701 T AT94925701 T AT 94925701T AT E242253 T1 ATE242253 T1 AT E242253T1
Authority
AT
Austria
Prior art keywords
compounds
inhibitors
antiproliferants
gaft
compounds usable
Prior art date
Application number
AT94925701T
Other languages
English (en)
Inventor
Michael D Varney
William H Romines
Cynthia L Palmer
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of ATE242253T1 publication Critical patent/ATE242253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94925701T 1994-07-28 1994-07-28 Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind ATE242253T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG1996008313A SG44827A1 (en) 1994-07-28 1994-07-28 Compounds useful as antiproliferative agents and garft inhibitors
PCT/US1994/008522 WO1996003407A1 (en) 1994-07-28 1994-07-28 Compounds useful as antiproliferative agents and garft inhibitors

Publications (1)

Publication Number Publication Date
ATE242253T1 true ATE242253T1 (de) 2003-06-15

Family

ID=26665124

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925701T ATE242253T1 (de) 1994-07-28 1994-07-28 Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind

Country Status (13)

Country Link
EP (1) EP0783507B1 (de)
JP (1) JP3473956B2 (de)
AT (1) ATE242253T1 (de)
AU (1) AU698868B2 (de)
DE (1) DE69432801T2 (de)
DK (1) DK0783507T3 (de)
ES (1) ES2201079T3 (de)
FI (1) FI112661B (de)
NO (1) NO308997B1 (de)
NZ (1) NZ271766A (de)
RU (1) RU2136686C1 (de)
SG (1) SG44827A1 (de)
WO (1) WO1996003407A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123550A (en) * 1977-10-31 1978-10-31 Syntex (U.S.A.) Inc. Bicyclo[3.1.0]hexylethylaminocarbonyl-substituted heteroaryl cardiovascular agents
ZA861235B (en) * 1985-03-08 1986-10-29 Univ Princeton Pyrido(2,3-d)pyrimidine derivatives
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
US5739141A (en) * 1992-12-16 1998-04-14 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds

Also Published As

Publication number Publication date
FI112661B (fi) 2003-12-31
JP3473956B2 (ja) 2003-12-08
EP0783507B1 (de) 2003-06-04
FI970318A (fi) 1997-03-05
DE69432801T2 (de) 2003-12-04
NO970350D0 (no) 1997-01-27
NO308997B1 (no) 2000-11-27
NZ271766A (en) 1999-01-28
FI970318A0 (fi) 1997-01-24
ES2201079T3 (es) 2004-03-16
EP0783507A1 (de) 1997-07-16
RU2136686C1 (ru) 1999-09-10
AU7552094A (en) 1996-02-22
NO970350L (no) 1997-03-12
SG44827A1 (en) 1997-12-19
WO1996003407A1 (en) 1996-02-08
DK0783507T3 (da) 2003-09-15
AU698868B2 (en) 1998-11-12
JPH10504541A (ja) 1998-05-06
DE69432801D1 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE206122T1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
DE69428025T2 (de) Proteinkinase C-Inhibitoren
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
IL118544A0 (en) Substituted amino pyridyl and pyrimidine containing compounds
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
YU31392A (sh) Derivati heterocikličnih-cikličnih amina
UA27100A1 (uk) Заміщеhі піроли, що мають активhість іhгібіторів протеіhкіhази с, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі і фармацевтичhа композиція
ES2145122T3 (es) Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
DE69514100T2 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
ATE242253T1 (de) Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0783507

Country of ref document: EP

REN Ceased due to non-payment of the annual fee